SCHEDULE 13D/A: Sofinnova Group's Stake in HOOKIPA Pharma Dips to 2.6% Following Share Dilution
Schedule 13D Amendment
Sofinnova Capital VI FCPR and its affiliates have reported a decrease in their beneficial ownership of HOOKIPA Pharma Inc. to 2.6%, primarily due to an increase in the issuer's outstanding shares from a June 2023 public offering.
Summary
- Sofinnova Capital VI FCPR, Sofinnova Partners SAS, and their investment committee members (Antoine Papiernik, Henrijette Richter, Maina Bhaman, Graziano Seghezzi, Anta Gkelou, and Karl Naegler) have filed an Amendment No. 5 to their Schedule 13D.
- The filing indicates a decrease in their beneficial ownership of HOOKIPA Pharma Inc.'s Common Stock to 2.6%.
- This reduction in percentage ownership is not due to any sales or transactions by the Reporting Persons but rather an increase in the total number of HOOKIPA Pharma's outstanding shares.
- The increase in outstanding shares resulted from a public offering of Common Stock completed by HOOKIPA Pharma Inc. in June 2023.
- As of November 11, 2024, HOOKIPA Pharma had 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding, totaling 12,054,539 shares, which was used to calculate the 2.6% ownership.
- The Reporting Persons collectively beneficially own 314,259 shares of HOOKIPA Pharma Inc. Common Stock.
Sentiment
Score: 5
Explanation: The document is a factual update on beneficial ownership percentage change due to past dilution. It is neutral in tone regarding the company's performance, but the dilution itself is a neutral to slightly negative event for existing shareholders' proportional ownership.
Negatives
- The reporting persons' percentage ownership in HOOKIPA Pharma Inc. has decreased from a previously higher stake due to share dilution.
- Existing shareholders, including the reporting persons, experienced a reduction in their proportional ownership of the company due to the public offering in June 2023.
Risks
- Dilution of existing shareholder ownership due to the issuance of new shares, as evidenced by the public offering in June 2023.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of changes in beneficial ownership and does not provide specific insights into broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors. It primarily reflects the impact of a past capital raise on a specific investor's stake.
Stakeholder Impact
- Shareholders: Existing shareholders, including the reporting persons, experienced dilution of their ownership percentage due to the public offering.
Key Dates
| Date | Description |
|---|---|
| 2019-04-30 | Original Schedule 13D filed with the SEC. |
| 2021-02-02 | Amendment No. 1 to Schedule 13D filed. |
| 2021-03-31 | Amendment No. 2 to Schedule 13D filed. |
| 2021-04-22 | Amendment No. 3 to Schedule 13D filed. |
| 2023-02-13 | Amendment No. 4 to Schedule 13D filed. |
| 2023-06 | HOOKIPA Pharma Inc. closed a public offering of Common Stock, substantially increasing outstanding shares. |
| 2024-11-11 | Date as of which 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock were outstanding, as reported in HOOKIPA's Form 10-Q. |
| 2024-11-14 | Date HOOKIPA's Form 10-Q was filed with the SEC, reporting outstanding shares as of November 11, 2024. |
| 2025-02-14 | Date of event which requires filing of this statement (Amendment No. 5 filing date). |
Keywords
HOOKIPA Pharma Inc., Sofinnova Capital VI FCPR, Sofinnova Partners SAS, Schedule 13D, beneficial ownership, share dilution, public offering, common stock, SEC filing, investment fund, biotechnology, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.